Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor may offer advantages in the treatment of Post-Myocardial Infarction
Considerable opportunity remains for an Antiplatelet therapy that, combined with Aspirin, causes less bleeding than the combination of Plavix/Iscover and Aspirin, according to a new report from Decision Resources

Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Rexahn Pharmaceuticals will be presenting at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008

Simvastatin leads Pfizer's Lipitor in second-line patient share for the treatment of Dyslipidemia
Results from the Enhance trial impacting physician prescribing patterns, according to a new report from Decision Resources

Launches of at least 15 new biologic therapies by 2017 will expand treatment options for Immune and Inflammatory Diseases
High-priced emerging immunomodulators will drive robust market growth over the next decade, according to a new report from Decision Resources

Lawson scientist researches best time to perform cleft alveolar surgery
London Scientist Researches the Best Time to Perform Cleft Alveolar Surgery - Findings change the way doctors perform surgery around the world

Spinal Cord Research Heads New Funding in London
A researcher striving to help patients recover from spinal cord injuries headlines more than $10.5 million in funding from the Canadian Institutes of Health Research (CIHR) at The University of Western Ontario and Lawson Health Research Institute

Current and emerging drugs have not yet shown an advantage in survival over Velcade in the treatment of Relapsed Multiple Myeloma
A drug used in combination with Velcade that could improve overall survival would earn a 45 percent patient share, according to a new report from Decision Resources

Spinal Cord Research Heads New Funding in London
More Than $10 Million for Leading Health Research at City Institutions

New City-Wide Centre for Research Commercialization To Help Drive Job Creation and Economic Development in London
WORLDiscoveriesTM, a new technology transfer consortium formed by London's research institutions, will develop small- and medium-sized enterprises in the region, creating 250 jobs and generating $50 million in investment over the next three years.

University researchers receive cancer funding
Robarts Research Institute scientist Paula Foster and Schulich School of Medicine & Dentistry's David Litchfield will receive more than $885,000 to fund innovative research projects.

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections

Newly launched B. Braun Exadoral® oral dispensers help reduce liquid medication errors
The Exadoral oral dispenser range is one of the latest supplements to B. Braun's range of products helping reduce the potential for medication errors, improve best practice and meet patient safety needs.

Current and emerging Insomnia drugs have minimal advantages over Sanofi-Aventis's Ambien in causing the onset of sleep
However, Somaxon's Silenor will replace Ambien as the clinical gold standard for Insomnia in 2011, according to a new report from Decision Resources

aespironics demonstrates its active-mesh technology
DPI company aespironics Ltd. completes first demonstration of its novel dry-powder inhaler (DPI) technology

Lawson Scientists are on the 'hunt' for a cure for cancer
Scientists at the Lawson Health Research Institute (Lawson) in London are currently testing new treatments aimed at reducing or eliminating the capacity of cancer cells to get around the immune system.

Avastin used in combination with drugs from Bristol-Myers Squibb has advantages in survival rates over the current sales-leading therapy for advanced Ovarian Cancer
Avastin used in combination with Taxol and Paraplatin will become the clinical gold standard treatment by 2011, according to a new report from Decision Resources

Concern from doctors regarding the cardiovascular safety of GlaxoSmithKline's Avandia increases nine-fold following publication of meta-analysis
Nearly three-quarters of physicians have switched patients to Merck's Januvia, according to a new report from Decision Resources

A drug that carries a lower risk of weight gain than AstraZeneca's Seroquel and has antimanic and antidepressant effects would earn a 30 percent patient share in Bipolar Disorder treatment
Seroquel's successor, Seroquel XR, will earn a 16 percent patient share in the Bipolar Disorder market by 2016, according to a new report from Decision Resources

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers

S.C. Ferguson Memorial Symposium
Wednesday, April 23, 2008 at University Hospital, London, Ontario, Canada